STOCK TITAN

Intellia Therapeutics, Inc - NTLA STOCK NEWS

Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.

The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.

Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.

The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.

Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.

Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.

For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.

Rhea-AI Summary

Intellia Therapeutics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency for a protocol amendment in its Phase 1 study of NTLA-2001, a CRISPR/Cas9-based therapy. The amendment allows enrollment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study aims to assess safety and efficacy, expanding its participant pool to include up to 36 adults with different forms of ATTR-CM. NTLA-2001 is pioneering as a potentially curative treatment, with previous interim data showing significant TTR level reductions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) announced it will present data from its ex vivo research and development at the 63rd American Society of Hematology Annual Meeting, from December 11-14, 2021. Key presentations include a novel allogeneic technology that mitigates host cell rejection and details on the clinical-scale manufacturing of NTLA-5001, a T cell therapeutic for acute myeloid leukemia. The data aims to advance engineered cell therapies for life-threatening diseases, showcasing Intellia's commitment to CRISPR/Cas9 technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NTLA) announced significant advancements in its clinical pipeline. They initiated dosing of Cohort 4 in the Phase 1 study of NTLA-2001, targeting ATTR amyloidosis, with data expected in Q1 2022. The company accelerated plans for NTLA-2001 in patients with ATTR-CM and is on track to launch first-in-human studies for NTLA-2002 (HAE) and NTLA-5001 (AML) by year-end. Intellia also nominated NTLA-3001 for AATD and reported a robust cash position of $1.1 billion. However, the company faced a net loss of $71.6 million in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) will present its third quarter 2021 financial results and operational highlights on November 4, 2021, at 8 a.m. ET. The call can be accessed via U.S. dial-in at 1-833-316-0545 or international at 1-412-317-5726. It will feature crucial insights on the company's advancements in developing curative CRISPR/Cas9 therapeutics. Additionally, a replay will be available on the company's Investors & Media section after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.02%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) announced that the FDA granted orphan drug designation to NTLA-2001 for treating ATTR amyloidosis. This investigational therapy is the first CRISPR treatment designed for systemic use. NTLA-2001 aims to be a potential single-dose treatment, possibly halting the disease’s complications. Intellia is committed to advancing its genome editing platform, with NTLA-2001 currently in Phase 1 trials. The FDA's designation provides development incentives, echoing a similar approval from the European Commission earlier this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) recently showcased significant preclinical advancements in its CRISPR/Cas9 genome editing platform at the ESGCT Annual Congress. Key highlights included the development of immune-evading allogeneic T cells, effective lipid nanoparticle delivery methods, and successful gene therapy results in non-human primates for treating alpha-1 antitrypsin deficiency (AATD). These findings support the company's strategy to progress its therapeutic candidates, including NTLA-5001 for acute myeloid leukemia, set to initiate clinical trials by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
Rhea-AI Summary

Intellia and SparingVision have announced a strategic collaboration to utilize Intellia's CRISPR/Cas9 technology for developing ocular therapies targeting three significant diseases. Intellia will grant SparingVision exclusive rights to its technology, receiving a 10% equity stake and potential milestone payments of up to $200 million per product. Additionally, Intellia may secure US commercialization rights for two targets. The collaboration aims to leverage both companies' strengths in genomic medicine and address unmet medical needs in ophthalmology. An investor webcast will provide further details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) has presented key findings at the 29th Annual Congress of the European Society of Gene & Cell Therapy. The company showcased its proprietary allogeneic T cell therapy platform designed to address immune rejection in therapeutic candidates for cancer and autoimmune diseases. Significant advancements include a lipid nanoparticle-based CRISPR/Cas9 delivery system and the first reported consecutive in vivo gene insertion and knockout in non-human primates aimed at treating alpha-1 antitrypsin deficiency (AATD). This work positions Intellia at the forefront of genome editing therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences clinical trial
-
Rhea-AI Summary

Intellia Therapeutics has received authorization from New Zealand's MEDSAFE to initiate a Phase 1/2 clinical study for NTLA-2002, a CRISPR/Cas9-based therapeutic aimed at treating hereditary angioedema (HAE). NTLA-2002 is designed to inactivate the KLKB1 gene, potentially providing a one-time treatment to prevent debilitating attacks associated with HAE. Patient enrollment is expected to start by year-end, with further regulatory applications planned globally. The program builds on insights gained from previous trials on NTLA-2001 for ATTR amyloidosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) will present at Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 10:30 a.m. ET. This clinical-stage genome editing company is focused on developing curative therapeutics using CRISPR/Cas9 technology through in vivo and ex vivo methods. A live webcast of the presentation will be available on their website approximately 15 minutes prior to the start. A replay will be accessible for 14 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences

FAQ

What is the current stock price of Intellia Therapeutics (NTLA)?

The current stock price of Intellia Therapeutics (NTLA) is $12.18 as of December 20, 2024.

What is the market cap of Intellia Therapeutics (NTLA)?

The market cap of Intellia Therapeutics (NTLA) is approximately 1.3B.

What is the mission of Intellia Therapeutics?

Intellia Therapeutics aims to develop curative medicines using CRISPR/Cas9 gene editing technology.

What diseases is Intellia targeting with their CRISPR-based therapies?

Intellia targets genetically defined diseases such as ATTR amyloidosis, hereditary angioedema (HAE), sickle cell disease, and cystic fibrosis.

What are Intellia's key advancements in hereditary angioedema (HAE) treatment?

Intellia's NTLA-2002 program for HAE has shown a 95% reduction in monthly attack rates, with most patients remaining attack-free.

When was Intellia Therapeutics founded?

Intellia Therapeutics was founded in 2014.

Who are Intellia's key collaborators?

Intellia has collaborations with Regeneron, Novartis, and ReCode Therapeutics.

What is CRISPR/Cas9?

CRISPR/Cas9 is a gene editing technology that allows for precise modification of DNA sequences, adapted from a natural cellular process.

How does Intellia's in vivo program work?

Intellia's in vivo programs use CRISPR to edit disease-causing genes directly inside the human body.

What are the recent financial highlights of Intellia Therapeutics?

Intellia recently reported strong enrollment progress in their Phase 3 MAGNITUDE trial for NTLA-2001.

What is the scope of Intellia's collaboration with ReCode Therapeutics?

The collaboration aims to develop genomic medicines for cystic fibrosis using Intellia's CRISPR-based platform and ReCode's SORT LNP delivery platform.

Where can I find more information about Intellia Therapeutics?

Visit Intellia's website at www.intelliatx.com and follow them on Twitter @intelliatx.

Intellia Therapeutics, Inc

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

1.26B
100.15M
1.21%
91.4%
16.07%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
CAMBRIDGE